161975-39-9

Basic information

• Product Name: 1-BOC-4-METHANESULFONYLOXYMETHYL-PIPERIDINE
• Synonyms: TERT-BUTYL 4-([(METHYLSULFONYL)OXY]METHYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE;1-BOC-4-METHANESULFONYLOXYMETHYL-PIPERIDINE;1-N-BOC-4-METHANESULFONYLOXYMETHYLPIPERIDINE;1-piperidinecarboxylic acid, 4-[[(methylsulfonyl)oxy]methy;tert-butyl 4-{[(methylsulfonyl)oxy]methyl}piperidine-1-carboxylate;1-Boc-4-(MethylsulfonyloxyMethyl)piperidine;N-Boc-4-MethanesulfonyloxyMethyl-piperidine;tert-Butyl 4-MethylsulfonyloxyMethyl-1-piperidinecarboxylate
• CAS NO: 161975-39-9
• Molecular Formula: C₁₂H₂₃NO₅S
• Molecular Weight: 293.38
• Mol File: 161975-39-9.mol

Chemical Properties

• Melting Point: 73-76°C
• Boiling Point: 418.8 °C at 760 mmHg
• Flash Point: 207.1 °C
• Appearance: /
• Density: 1.175g/cm³
• Vapor Pressure: 3.2E-07mmHg at 25°C
• Refractive Index: 1.487
• PKA: -1.96±0.40(Predicted)
• CAS DataBase Reference: 1-BOC-4-METHANESULFONYLOXYMETHYL-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-METHANESULFONYLOXYMETHYL-PIPERIDINE(161975-39-9)
• EPA Substance Registry System: 1-BOC-4-METHANESULFONYLOXYMETHYL-PIPERIDINE(161975-39-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 161975-39-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-BOC-4-METHANESULFONYLOXYMETHYL-PIPERIDINE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into complex molecular structures, contributing to the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
1-BOC-4-METHANESULFONYLOXYMETHYL-PIPERIDINE is used as a building block for the preparation of various bioactive compounds, leveraging its unique structure and reactivity to facilitate the creation of diverse chemical entities with potential applications in medicine and other fields.
Used in Chemical Synthesis and Drug Discovery:
1-BOC-4-METHANESULFONYLOXYMETHYL-PIPERIDINE is used as a valuable intermediate in the synthesis of complex organic molecules, playing a crucial role in the discovery and development of new chemical entities with potential pharmaceutical, agrochemical, or other industrial applications.

InChI:InChI=1/C12H23NO5S/c1-12(2,3)18-11(14)13-7-5-10(6-8-13)9-17-19(4,15)16/h10H,5-9H2,1-4H3

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6457-49-4 4-piperidinemethanol 
• 7143-01-3 Methanesulfonic anhydride 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 1126-09-6 4-carbethoxypiperidine 
• 138022-91-0 tert-butyl 4-(methoxymethylene)piperidine-1-carboxylate 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 498-94-2 isonipecotic acid 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 

Downstream Products

• 176967-61-6 1-(tert-butoxycarbonyl)-4-(4-cyanophenoxymethyl)piperidine 
• 189339-70-6 2-Chlorobenzenesulfonic acid 3-[[N-(tert-butoxycarbonyl)piperidin-4-yl]methoxy]-5-methylphenyl ester 
• 189340-73-6 Benzenesulfonic acid 3-[[N-(tert-butoxycarbonyl)piperidin-4-yl]methoxy]-5-methylphenyl ester 
• 189339-61-5 2-Chlorobenzenesulfonic acid 3-[[N-(tert-butoxycarbonyl)piperidin-4-yl]methoxy]phenyl ester 
• 189341-05-7 4-[3-methyl-5-(toluene-3-sulfonyloxy)-phenoxymethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 189340-86-1 4-[3-(2-chloro-benzenesulfonyloxy)-5-methoxy-phenoxymethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 189340-80-5 3-Chlorobenzenesulfonic acid 3-[[N-(tert-butoxycarbonyl)piperidin-4-yl]methoxyl]-5-methylphenyl ester 
• 189341-13-7 4-[3-(2-chloro-benzenesulfonyloxy)-5-ethyl-phenoxymethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 189340-53-2 1-Naphthalenesulfonic acid 3-[[N-(tert-butoxycarbonyl)piperidin-4-yl]methoxy]-5-methylphenyl ester 
• 189341-23-9 2,3-Dichlorobenzenesulfonic acid 3-[[N-(tert-butoxycarbonyl)piperidin-4-yl]methoxy]-5-methylphenyl ester 
• 189341-02-4 4-[3-methyl-5-(2-trifluoromethyl-benzenesulfonyloxy)-phenoxymethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 189340-02-1 2-Chlorobenzenesulfonic acid 3-[[1-N-(tert-butoxycarbonyl)piperidin-4-yl]methoxy]-5-carbomethoxyphenyl ester 
• 189340-63-4 4-[3-methyl-5-(3-trifluoromethyl-benzenesulfonyloxy)-phenoxymethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 325290-50-4 tert-butyl 4-(azidomethyl)piperidine-1-carboxylate 

Relevant articles and documents

Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase

The first chemical probe to primarily occupy the co-factor binding site of a Su(var)3-9, enhancer of a zeste, trithorax (SET) domain containing protein lysine methyltransferase (PKMT) is reported. Protein methyltransferases require S-adenosylmethionine (SAM) as a co-factor (methyl donor) for enzymatic activity. However, SAM itself represents a poor medicinal chemistry starting point for a selective, cell-active inhibitor given its extreme physicochemical properties and its role in multiple cellular processes. A previously untested medicinal chemistry strategy of deliberate file enrichment around molecules bearing the hallmarks of SAM, but with improved lead-like properties from the outset, yielded viable hits against SET and MYND domain-containing protein 2 (SMYD2) that were shown to bind in the co-factor site. These leads were optimized to identify a highly biochemically potent, PKMT-selective, and cell-active chemical probe. While substrate-based inhibitors of PKMTs are known, this represents a novel, co-factor-derived strategy for the inhibition of SMYD2 which may also prove applicable to lysine methyltransferase family members previously thought of as intractable.

INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER

The present invention relates to indole derivatives of formula (I') as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.

Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands

With the aim to obtain potent adenosine A2A receptor (A2AR) ligands, a series of eighteen derivatives of 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide (SYN-115, Tozadenant) were designed and synthesized. The target compounds were obtained by a chemical building block principle that involved reaction of the appropriate aminobenzothiazole phenyl carbamates with either commercially available or readily synthesized functionalized piperidines. Their affinity and subtype selectivity with regard to human adenosine A1-and A2A receptors were determined using radioligand binding assays. Ki values for human A2AR ranged from 2.4 to 38 nM, with more than 120-fold selectivity over A1 receptors for all evaluated compounds except 13k which had a Ki of 361 nM and 18-fold selectivity. The most potent fluorine-containing derivatives 13e, 13g and 13l exhibited Ki values of 4.9 nM, 3.6 nM and 2.8 nM for the human A2AR. Interestingly, the corresponding values for rat A2AR were found to be four to five times higher. Their binding to A2AR was further confirmed by radiolabeling with 18F and in vitro autoradiography in rat brain slices, which showed almost exclusive striatal binding and complete displacement by the A2AR antagonist ZM 241385. We conclude that these compounds represent potential candidates for the visualization of the A2A receptor and open pathways to novel therapeutic treatments of neurodegenerative disorders or cancer.

Synthesis and evaluation of tetrahydroisoquinoline derivatives against Trypanosoma brucei rhodesiense

Human African Trypanosomiasis (HAT) is a neglected tropical disease caused by the parasitic protozoan Trypanosoma brucei (T. b.), and affects communities in sub-Saharan Africa. Previously, analogues of a tetrahydroisoquinoline scaffold were reported as having in vitro activity (IC50 = 0.25–70.5 μM) against T. b. rhodesiense. In this study the synthesis and antitrypanosomal activity of 80 compounds based around a core tetrahydroisoquinoline scaffold are reported. A detailed structure activity relationship was revealed, and five derivatives (two of which have been previously reported) with inhibition of T. b. rhodesiense growth in the sub-micromolar range were identified. Four of these (3c, 12b, 17b and 26a) were also found to have good selectivity over mammalian cells (SI > 50). Calculated logD values and preliminary ADME studies predict that these compounds are likely to have good absorption and metabolic stability, with the ability to passively permeate the blood brain barrier. This makes them excellent leads for a blood-brain barrier permeable antitrypanosomal scaffold.

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

ION CHANNEL ANTAGONISTS/BLOCKERS AND USES THEREOF

Provided are ion channel antagonists/blockers and uses thereof. Specifically, it provides the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details. Provided is also pharmaceutical composition useful for treatment of heart disease and other ion channel related diseases.

BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE

The disclosure provides BRD9 bifunctional compounds of Formula (A) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, to their preparation, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases and disorders mediated by a bromodomain-containing protein, such as bromodoma in-containing protein 9 (BRD9)

SIGMA-1 RECEPTOR LIGANDS AND USES THEREOF

The present invention relates to the field of medicine. More specifically, the present invention relates to compounds that are sigma-1 receptor agonists and their use for the treatment of central nervous system disorders, including cognitive or neurodegen

PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR

Disclosed are a pyrimidinyl group-containing tricyclic compound and applications thereof in preparing a cancer-treating medicament. Specifically disclosed are a compound as represented by formula (I), a pharmaceutically acceptable salt of same, or an isomer thereof.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.